Alan Huang

8.8k total citations · 3 hit papers
64 papers, 3.3k citations indexed

About

Alan Huang is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alan Huang has authored 64 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Molecular Biology, 24 papers in Oncology and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alan Huang's work include Cancer-related gene regulation (11 papers), PI3K/AKT/mTOR signaling in cancer (10 papers) and Advanced Breast Cancer Therapies (9 papers). Alan Huang is often cited by papers focused on Cancer-related gene regulation (11 papers), PI3K/AKT/mTOR signaling in cancer (10 papers) and Advanced Breast Cancer Therapies (9 papers). Alan Huang collaborates with scholars based in United States, Switzerland and Singapore. Alan Huang's co-authors include Barbara L. Weber, Alan Ashworth, Levi A. Garraway, William R. Sellers, Robert Schlegel, Dejan Juric, Giordano Caponigro, Alice Loo, Howard A. Burris and Hope S. Rugo and has published in prestigious journals such as Journal of Clinical Oncology, Genes & Development and SHILAP Revista de lepidopterología.

In The Last Decade

Alan Huang

60 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas

2012 410 citations Alan Huang et al. Cancer Cell profile →
CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors

2014 351 citations Sadhna Vora, Dejan Juric et al. Cancer Cell profile →
Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

2018 302 citations Dejan Juric, Jordi Rodón et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alan Huang United States	24	2.3k	1.3k	917	533	363	64	3.3k
Pieter J.A. Eichhorn Singapore	25	2.7k 1.2×	1.3k 1.1×	525 0.6×	682 1.3×	321 0.9×	34	3.6k
Vanessa Rodrik-Outmezguine United States	16	2.1k 1.0×	943 0.7×	561 0.6×	458 0.9×	233 0.6×	32	2.8k
Young Hwa Soung South Korea	30	2.3k 1.0×	1.2k 0.9×	621 0.7×	669 1.3×	291 0.8×	70	3.2k
Caterina Nardella United States	19	3.1k 1.4×	1.2k 0.9×	896 1.0×	864 1.6×	240 0.7×	26	4.2k
Terence O’Reilly Switzerland	24	2.0k 0.9×	1.1k 0.9×	668 0.7×	421 0.8×	239 0.7×	36	3.2k
Andrew Krivoshik United States	19	1.6k 0.7×	876 0.7×	1.3k 1.4×	598 1.1×	481 1.3×	56	3.3k
Kimberly Stegmaier United States	38	3.6k 1.6×	1.0k 0.8×	679 0.7×	757 1.4×	368 1.0×	135	5.4k
Antonella Papa United States	18	2.4k 1.1×	855 0.7×	390 0.4×	560 1.1×	247 0.7×	29	3.1k
Danan Li United States	16	2.3k 1.0×	1.6k 1.2×	1.0k 1.1×	496 0.9×	137 0.4×	21	3.2k
Marta Guzmán Spain	17	2.2k 1.0×	2.8k 2.2×	1.3k 1.4×	589 1.1×	551 1.5×	31	4.4k

Countries citing papers authored by Alan Huang

Since Specialization

Citations

This map shows the geographic impact of Alan Huang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Huang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Huang more than expected).

Fields of papers citing papers by Alan Huang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Huang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Huang. The network helps show where Alan Huang may publish in the future.

Co-authorship network of co-authors of Alan Huang

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Huang. A scholar is included among the top collaborators of Alan Huang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Huang. Alan Huang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Briggs, Kimberly J., Kevin M. Cottrell, Minjie Zhang, et al.. (2025). TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers. Translational Oncology. 52. 102264–102264. 6 indexed citations

Borcherding, Dana C., Yang Lyu, Anthony P.W. Yuen, et al.. (2025). MTA-Cooperative PRMT5 Inhibitors Are Efficacious in MTAP-Deleted Malignant Peripheral Nerve Sheath Tumor Models. Clinical Cancer Research. 31(22). 4779–4789.

Lazarides, Katherine, Yi Yu, Shangtao Liu, et al.. (2025). CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors. Molecular Cancer Therapeutics. 24(9). 1466–1479. 1 indexed citations

Cottrell, Kevin M., Kimberly J. Briggs, Alice Tsai, et al.. (2025). Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion. Journal of Medicinal Chemistry. 68(5). 5097–5119. 7 indexed citations

Borcherding, Dana C., Xiaochun Zhang, Minjie Zhang, et al.. (2023). EXTH-63. MTA-COOPERATIVE PRMT5 INHIBITORS ARE EFFICACIOUS IN MTAP-DELETED MALIGNANT PERIPHERAL NERVE SHEATH TUMOR MODELS. Neuro-Oncology. 25(Supplement_5). v238–v238. 3 indexed citations

Wong, James S.H., Sarah Masson, Alan Huang, et al.. (2022). Cost Analysis of Buprenorphine Extended-Release Injection Versus Sublingual Buprenorphine/Naloxone Tablets in a Correctional Setting. Journal of Correctional Health Care. 28(6). 368–371. 5 indexed citations

Briggs, Karen K., Erik Wilker, Charles B. Davis, et al.. (2022). 24P Evidence for synergy between TNG908, an MTAPnull-selective PRMT5 inhibitor, and sotorasib in an MTAPnull/KRASG12C xenograft model. Annals of Oncology. 33. S12–S12. 3 indexed citations

DeWeirdt, Peter C., Kendall R Sanson, Annabel K. Sangree, et al.. (2020). Optimization of AsCas12a for combinatorial genetic screens in human cells. Nature Biotechnology. 39(1). 94–104. 110 indexed citations

Huynh, Hung, Thi Bich Uyen Le, Huai-Xiang Hao, et al.. (2020). FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma. Experimental & Molecular Medicine. 52(11). 1857–1868. 19 indexed citations

10.

Baltschukat, Sabrina, Barbara Schacher Engstler, Alan Huang, et al.. (2019). Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation. Clinical Cancer Research. 25(10). 3164–3175. 105 indexed citations

11.

Huang, Alan, Levi A. Garraway, Alan Ashworth, & Barbara L. Weber. (2019). Synthetic lethality as an engine for cancer drug target discovery. Nature Reviews Drug Discovery. 19(1). 23–38. 301 indexed citations

12.

Juric, Dejan, Jordi Rodón, Josep Tabernero, et al.. (2018). Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Journal of Clinical Oncology. 36(13). 1291–1299. 302 indexed citations breakdown →

13.

Huynh, Hung, Huai-Xiang Hao, Stephen L. Chan, et al.. (2015). Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus. Molecular Cancer Therapeutics. 14(5). 1224–1235. 60 indexed citations

14.

Li, Fang, Hung Huynh, Xiaoyan Li, et al.. (2015). FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors. Cancer Discovery. 5(4). 438–451. 85 indexed citations

15.

Vora, Sadhna, Dejan Juric, Mari Mino–Kenudson, et al.. (2014). CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors. Cancer Cell. 26(1). 136–149. 351 indexed citations breakdown →

16.

Wiederschain, Dmitri, Lin Chen, Alice Loo, et al.. (2009). Single-vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle. 8(3). 498–504. 306 indexed citations

17.

Gaither, Alex, Dale Porter, Yao Yao, et al.. (2007). A Smac Mimetic Rescue Screen Reveals Roles for Inhibitor of Apoptosis Proteins in Tumor Necrosis Factor-α Signaling. Cancer Research. 67(24). 11493–11498. 178 indexed citations

18.

Huang, Alan, et al.. (2004). Functional silencing of hepatic microsomal glucose‐6‐phosphatase gene expression in vivo by adenovirus‐mediated delivery of short hairpin RNA. FEBS Letters. 558(1-3). 69–73. 12 indexed citations

19.

Corey, David R., et al.. (1995). Strand invasion by oligonucleotide-nuclease conjugates. Bioconjugate Chemistry. 6(1). 93–100. 25 indexed citations

20.

Brenner, Karl‐Heinz & Alan Huang. (1985). An Optical Processor Based on Symbolic Substitution. WA4–WA4. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact